{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T03:46:30Z","timestamp":1792035990927,"version":"4.4.0"},"reference-count":60,"publisher":"Bioscientifica","issue":"8","license":[{"start":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T00:00:00Z","timestamp":1782950400000},"content-version":"vor","delay-in-days":77,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["journals.bioscientifica.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,8,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Telomerase reverse transcriptase (TERT) promoter mutations are associated with aggressive clinicopathological features of papillary thyroid cancer (PTC). However, their independent prognostic value remains unclear. This study aimed to evaluate the prognostic significance of TERT promoter mutations (TPMs) in predicting early treatment outcomes and event-free survival (EFS) in patients with PTC. We retrospectively analyzed a prospective cohort; patients underwent surgery at a single tertiary referral center between 2019 and 2022. Patients underwent thyroidectomy, selective postoperative radioactive iodine ablation, and levothyroxine suppression therapy. Propensity score matching (PSM, 1:1) was applied to adjust for baseline clinicopathological differences. Of 10,642 patients with available molecular data, 115 (1.1%) harbored TPMs. After PSM, 90 matched pairs of patients with TERT-wild-type and TERT-mutant tumors were analyzed. Early treatment responses at 1 and 2 years post-treatment and EFS were evaluated. Early treatment responses did not differ significantly between groups at 1 year (P = 0.212) and 2 years (P = 0.571). However, patients with TERT-mutant tumors had fewer excellent responses and higher rates of structural incomplete response. During follow-up, the TERT-mutant group experienced more recurrences and one disease-specific death. Cumulative EFS was significantly poorer in the TERT-mutant group than in the TERT-wild-type group (P = 0.022). Despite their low prevalence, TPMs were independently associated with adverse oncological outcomes, including higher rates of recurrence and mortality. TPMs may serve as valuable prognostic markers for early risk stratification in PTC.<\/jats:p>","DOI":"10.1530\/erc-25-0424","type":"journal-article","created":{"date-parts":[[2026,4,16]],"date-time":"2026-04-16T16:09:50Z","timestamp":1776355790000},"update-policy":"https:\/\/doi.org\/10.1530\/crossmarkpolicy-8","source":"Crossref","is-referenced-by-count":1,"title":["Value of TERT promoter mutations for early outcomes in papillary thyroid cancer"],"prefix":"10.1530","volume":"33","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7791-2994","authenticated-orcid":true,"given":"Min Jhi","family":"Kim","sequence":"first","affiliation":[{"name":"Department of Surgery, CHA Ilsan Medical Center, CHA University School of Medicine 1 , , ,","place":["Goyang-si, Gyeonggi-do, South Korea"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1871-686X","authenticated-orcid":true,"given":"Daham","family":"Kim","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Institute of Endocrine Research, Yonsei University College of Medicine 2 , ,","place":["Seoul, South Korea"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hye Sun","family":"Lee","sequence":"additional","affiliation":[{"name":"Biostatistics Collaboration Unit, Yonsei University College of Medicine 3 , ,","place":["Seoul, South Korea"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Se Hee","family":"Park","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Institute of Endocrine Research, Yonsei University College of Medicine 2 , ,","place":["Seoul, South Korea"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eun Jin","family":"Kim","sequence":"additional","affiliation":[{"name":"Department of Surgery, Yonsei University College of Medicine 4 , ,","place":["Seoul, South Korea"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin Kyong","family":"Kim","sequence":"additional","affiliation":[{"name":"Department of Surgery, Yonsei University College of Medicine 4 , ,","place":["Seoul, South Korea"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sang-Wook","family":"Kang","sequence":"additional","affiliation":[{"name":"Department of Surgery, Yonsei University College of Medicine 4 , ,","place":["Seoul, South Korea"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jandee","family":"Lee","sequence":"additional","affiliation":[{"name":"Department of Surgery, Yonsei University College of Medicine 4 , ,","place":["Seoul, South Korea"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jong Ju","family":"Jeong","sequence":"additional","affiliation":[{"name":"Department of Surgery, Yonsei University College of Medicine 4 , ,","place":["Seoul, South Korea"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Woong Youn","family":"Chung","sequence":"additional","affiliation":[{"name":"Department of Surgery, Yonsei University College of Medicine 4 , ,","place":["Seoul, South Korea"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6852-1190","authenticated-orcid":true,"given":"Kee-Hyun","family":"Nam","sequence":"additional","affiliation":[{"name":"Department of Surgery, Yonsei University College of Medicine 4 , ,","place":["Seoul, South Korea"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"416","published-online":{"date-parts":[[2026,4,16]]},"reference":[{"key":"2026082106561092400_bib1","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1111\/1440-1681.13223","article-title":"Role of telomerase in the tumour microenvironment","volume":"47","author":"Liu","year":"2020","journal-title":"Clin Exp Pharmacol Physiol"},{"key":"2026082106561092400_bib2","doi-asserted-by":"crossref","first-page":"1528","DOI":"10.1111\/j.1349-7006.2008.00878.x","article-title":"Understanding and exploiting hTERT promoter regulation for diagnosis and treatment of human cancers","volume":"99","author":"Kyo","year":"2008","journal-title":"Cancer Sci"},{"key":"2026082106561092400_bib3","article-title":"Exploring the role of TERT in thyroid cancer: a systematic review","volume":"213","author":"Maloberti","year":"2025","journal-title":"Crit Rev Oncol Hematol"},{"key":"2026082106561092400_bib4","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1038\/ng.3781","article-title":"Systematic analysis of telomere length and somatic alterations in 31 cancer types","volume":"49","author":"Barthel","year":"2017","journal-title":"Nat Genet"},{"key":"2026082106561092400_bib5","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1530\/ERC-16-0219","article-title":"TERT promoter mutations and long-term survival in patients with thyroid cancer","volume":"23","author":"Kim","year":"2016","journal-title":"Endocr Relat Cancer"},{"key":"2026082106561092400_bib6","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1016\/j.ejca.2015.03.010","article-title":"Recurrent TERT promoter mutations identified in a large-scale study of multiple tumour types are associated with increased TERT expression and telomerase activation","volume":"51","author":"Huang","year":"2015","journal-title":"Eur J Cancer"},{"key":"2026082106561092400_bib7","doi-asserted-by":"crossref","first-page":"2185","DOI":"10.1038\/ncomms3185","article-title":"Frequency of TERT promoter mutations in human cancers","volume":"4","author":"Vinagre","year":"2013","journal-title":"Nat Commun"},{"key":"2026082106561092400_bib8","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1530\/ERC-13-0210","article-title":"Highly prevalent TERT promoter mutations in aggressive thyroid cancers","volume":"20","author":"Liu","year":"2013","journal-title":"Endocr Relat Cancer"},{"key":"2026082106561092400_bib9","doi-asserted-by":"crossref","first-page":"652","DOI":"10.3803\/EnM.2022.1477","article-title":"Frequency of TERT promoter mutations in real-world analysis of 2,092 thyroid carcinoma patients","volume":"37","author":"Yang","year":"2022","journal-title":"Endocrinol Metab"},{"key":"2026082106561092400_bib10","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1007\/s12672-016-0256-3","article-title":"TERT promoter mutations in thyroid cancer","volume":"7","author":"Alzahrani","year":"2016","journal-title":"Horm Cancer"},{"key":"2026082106561092400_bib11","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1097\/PAS.0b013e3180309e6a","article-title":"Poorly differentiated thyroid carcinoma: the turin proposal for the use of uniform diagnostic criteria and an algorithmic diagnostic approach","volume":"31","author":"Volante","year":"2007","journal-title":"Am J Surg Pathol"},{"key":"2026082106561092400_bib12","first-page":"7","article-title":"Cancer statistics, 2019","volume":"69","author":"Siegel","year":"2019","journal-title":"CA Cancer J Clin"},{"key":"2026082106561092400_bib13","doi-asserted-by":"crossref","first-page":"1765","DOI":"10.1056\/NEJMp1409841","article-title":"Korea's thyroid-cancer \u201cepidemic\u201d \u2013 screening and overdiagnosis","volume":"371","author":"Ahn","year":"2014","journal-title":"N Engl J Med"},{"key":"2026082106561092400_bib14","doi-asserted-by":"crossref","first-page":"3112","DOI":"10.1007\/s12325-020-01391-1","article-title":"Papillary thyroid cancer-aggressive variants and impact on management: a narrative review","volume":"37","author":"Coca-Pelaz","year":"2020","journal-title":"Adv Ther"},{"key":"2026082106561092400_bib15","article-title":"Association between screening and the thyroid cancer \u201cepidemic\u201d in South Korea: evidence from a nationwide study","volume":"355","author":"Park","year":"2016","journal-title":"BMJ"},{"key":"2026082106561092400_bib16","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1089\/thy.2011.0535","article-title":"The impact of distant metastases at presentation on prognosis in patients with differentiated carcinoma of the thyroid gland","volume":"22","author":"Nixon","year":"2012","journal-title":"Thyroid"},{"key":"2026082106561092400_bib17","doi-asserted-by":"crossref","first-page":"1518","DOI":"10.1245\/s10434-008-9859-4","article-title":"Papillary thyroid carcinoma: factors influencing recurrence and survival","volume":"15","author":"Toniato","year":"2008","journal-title":"Ann Surg Oncol"},{"key":"2026082106561092400_bib18","doi-asserted-by":"crossref","first-page":"2685","DOI":"10.1007\/s00268-020-05521-2","article-title":"BRAF(V600E) mutation is associated with an increased risk of papillary thyroid cancer recurrence","volume":"44","author":"Enumah","year":"2020","journal-title":"World J Surg"},{"key":"2026082106561092400_bib19","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1159\/000443032","article-title":"Meta-analyses of association between BRAF(V600E) mutation and clinicopathological features of papillary thyroid carcinoma","volume":"38","author":"Zhang","year":"2016","journal-title":"Cell Physiol Biochem"},{"key":"2026082106561092400_bib20","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1001\/jama.2013.3190","article-title":"Association between BRAF V600E mutation and mortality in patients with papillary thyroid cancer","volume":"309","author":"Xing","year":"2013","journal-title":"JAMA"},{"key":"2026082106561092400_bib21","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1001\/jamaoncol.2016.3288","article-title":"Mortality risk stratification by combining BRAF V600E and TERT promoter mutations in papillary thyroid cancer: genetic duet of BRAF and TERT promoter mutations in thyroid cancer mortality","volume":"3","author":"Liu","year":"2017","journal-title":"JAMA Oncol"},{"key":"2026082106561092400_bib22","doi-asserted-by":"crossref","first-page":"18346","DOI":"10.18632\/oncotarget.7811","article-title":"BRAF and TERT promoter mutations in the aggressiveness of papillary thyroid carcinoma: a study of 653 patients","volume":"7","author":"Jin","year":"2016","journal-title":"Oncotarget"},{"key":"2026082106561092400_bib23","doi-asserted-by":"crossref","first-page":"1370","DOI":"10.1002\/cncr.29934","article-title":"Prognostic effects of TERT promoter mutations are enhanced by coexistence with BRAF or RAS mutations and strengthen the risk prediction by the ATA or TNM staging system in differentiated thyroid cancer patients","volume":"122","author":"Song","year":"2016","journal-title":"Cancer"},{"key":"2026082106561092400_bib24","doi-asserted-by":"crossref","first-page":"2718","DOI":"10.1200\/JCO.2014.55.5094","article-title":"BRAF V600E and TERT promoter mutations cooperatively identify the most aggressive papillary thyroid cancer with highest recurrence","volume":"32","author":"Xing","year":"2014","journal-title":"J Clin Oncol"},{"key":"2026082106561092400_bib25","doi-asserted-by":"crossref","first-page":"310","DOI":"10.4132\/jptm.2020.05.12","article-title":"Highly prevalent BRAF V600E and low-frequency TERT promoter mutations underlie papillary thyroid carcinoma in Koreans","volume":"54","author":"Kim","year":"2020","journal-title":"J Pathol Transl Med"},{"key":"2026082106561092400_bib26","doi-asserted-by":"crossref","first-page":"505","DOI":"10.3803\/EnM.2014.29.4.505","article-title":"The frequency and clinical implications of the BRAF(V600E) mutation in papillary thyroid cancer patients in Korea over the past two decades","volume":"29","author":"Hong","year":"2014","journal-title":"Endocrinol Metab"},{"key":"2026082106561092400_bib27","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/j.anl.2011.07.011","article-title":"BRAFV600E mutation does not serve as a prognostic factor in Korean patients with papillary thyroid carcinoma","volume":"39","author":"Ahn","year":"2012","journal-title":"Auris Nasus Larynx"},{"key":"2026082106561092400_bib28","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1111\/j.1365-2265.2006.02605.x","article-title":"The BRAF mutation is useful for prediction of clinical recurrence in low-risk patients with conventional papillary thyroid carcinoma","volume":"65","author":"Kim","year":"2006","journal-title":"Clin Endocrinol"},{"key":"2026082106561092400_bib29","doi-asserted-by":"crossref","first-page":"4928","DOI":"10.3390\/cancers14194928","article-title":"TERT promoter and BRAF V600E mutations in papillary thyroid cancer: a single-institution experience in Korea","volume":"14","author":"Kim","year":"2022","journal-title":"Cancers"},{"key":"2026082106561092400_bib30","article-title":"Current trends in the features of male thyroid cancer: retrospective evaluation of their prognostic value","volume":"98","author":"Kim","year":"2019","journal-title":"Medicine"},{"key":"2026082106561092400_bib31","doi-asserted-by":"crossref","first-page":"703","DOI":"10.3803\/EnM.2022.1553","article-title":"Update from the 2022 World Health Organization classification of thyroid tumors: a standardized diagnostic approach","volume":"37","author":"Jung","year":"2022","journal-title":"Endocrinol Metab"},{"key":"2026082106561092400_bib32","first-page":"93","article-title":"The eighth edition AJCC cancer staging manual: continuing to build a bridge from a population-based to a more \u201cpersonalized\u201d approach to cancer staging","volume":"67","author":"Amin","year":"2017","journal-title":"CA Cancer J Clin"},{"key":"2026082106561092400_bib33","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1089\/thy.2017.0102","article-title":"Updated American Joint Committee on Cancer\/Tumor-Node-Metastasis Staging System for differentiated and anaplastic thyroid cancer (eighth edition): what changed and why?","volume":"27","author":"Tuttle","year":"2017","journal-title":"Thyroid"},{"key":"2026082106561092400_bib34","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0242806","article-title":"Artificial intelligence to predict the BRAFV600E mutation in patients with thyroid cancer","volume":"15","author":"Yoon","year":"2020","journal-title":"PLoS One"},{"key":"2026082106561092400_bib35","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1089\/thy.2015.0020","article-title":"2015 American Thyroid Association Management Guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: the American Thyroid Association Guidelines task force on thyroid nodules and differentiated thyroid cancer","volume":"26","author":"Haugen","year":"2016","journal-title":"Thyroid"},{"key":"2026082106561092400_bib36","doi-asserted-by":"crossref","first-page":"348","DOI":"10.3349\/ymj.2023.0266","article-title":"No change in complications following thyroidectomy despite increase in thyroid cancer surgeries: a meta-regression analysis","volume":"65","author":"Lee","year":"2024","journal-title":"Yonsei Med J"},{"key":"2026082106561092400_bib37","doi-asserted-by":"crossref","first-page":"2754","DOI":"10.1210\/jc.2012-1533","article-title":"The utility of serum thyroglobulin measurement at the time of remnant ablation for predicting disease-free status in patients with differentiated thyroid cancer: a meta-analysis involving 3947 patients","volume":"97","author":"Webb","year":"2012","journal-title":"J Clin Endocrinol Metab"},{"key":"2026082106561092400_bib38","doi-asserted-by":"crossref","first-page":"4087","DOI":"10.1210\/jc.2019-00177","article-title":"Risk stratification in differentiated thyroid cancer: from detection to final follow-up","volume":"104","author":"Tuttle","year":"2019","journal-title":"J Clin Endocrinol Metab"},{"key":"2026082106561092400_bib39","doi-asserted-by":"crossref","first-page":"357","DOI":"10.3803\/EnM.2025.2465","article-title":"The initial risk stratification system for differentiated thyroid cancer: key updates in the 2024 Korean Thyroid Association Guideline","volume":"40","author":"Moon","year":"2025","journal-title":"Endocrinol Metab"},{"key":"2026082106561092400_bib40","doi-asserted-by":"crossref","first-page":"43","DOI":"10.3349\/ymj.2023.0582","article-title":"Concurrent Association of multifocality, bilaterality, and recurrence in pediatric papillary thyroid cancer patients","volume":"66","author":"Cho","year":"2025","journal-title":"Yonsei Med J"},{"key":"2026082106561092400_bib41","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1002\/pst.433","article-title":"Optimal caliper widths for propensity-score matching when estimating differences in means and differences in proportions in observational studies","volume":"10","author":"Austin","year":"2011","journal-title":"Pharm Stat"},{"key":"2026082106561092400_bib42","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1016\/j.cell.2013.01.010","article-title":"The role of telomeres in stem cells and cancer","volume":"152","author":"G\u00fcnes","year":"2013","journal-title":"Cell"},{"key":"2026082106561092400_bib43","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1136\/jclinpath-2018-205653","article-title":"TERT gene: its function and dysregulation in cancer","volume":"72","author":"Colebatch","year":"2019","journal-title":"J Clin Pathol"},{"key":"2026082106561092400_bib44","doi-asserted-by":"crossref","first-page":"3166","DOI":"10.1210\/clinem\/dgae327","article-title":"Coexisting RET\/PTC and TERT promoter mutation predict poor prognosis but effective RET and MEK targeting in thyroid cancer","volume":"109","author":"Zhang","year":"2024","journal-title":"J Clin Endocrinol Metab"},{"key":"2026082106561092400_bib45","doi-asserted-by":"crossref","first-page":"710","DOI":"10.3390\/cancers15030710","article-title":"MAPK pathway inhibitors in thyroid cancer: preclinical and clinical data","volume":"15","author":"Schubert","year":"2023","journal-title":"Cancers"},{"key":"2026082106561092400_bib46","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1016\/j.cell.2014.09.050","article-title":"Integrated genomic characterization of papillary thyroid carcinoma","volume":"159","author":"Cancer Genome Atlas Research Network","year":"2014","journal-title":"Cell"},{"key":"2026082106561092400_bib47","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1007\/s12020-019-02117-2","article-title":"Association between TERT promoter mutations and clinical behaviors in differentiated thyroid carcinoma: a systematic review and meta-analysis","volume":"67","author":"Yang","year":"2020","journal-title":"Endocrine"},{"key":"2026082106561092400_bib48","doi-asserted-by":"crossref","first-page":"2328","DOI":"10.1210\/en.2019-00315","article-title":"Impact of BRAF V600E and TERT promoter mutations on response to therapy in papillary thyroid cancer","volume":"160","author":"Trybek","year":"2019","journal-title":"Endocrinology"},{"key":"2026082106561092400_bib49","doi-asserted-by":"crossref","first-page":"942","DOI":"10.4143\/crt.2015.362","article-title":"TERT promoter mutations and tumor persistence\/recurrence in papillary thyroid cancer","volume":"48","author":"Myung","year":"2016","journal-title":"Cancer Res Treat"},{"key":"2026082106561092400_bib50","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1089\/thy.2015.0101","article-title":"TERT promoter mutations in papillary thyroid microcarcinomas","volume":"25","author":"de Biase","year":"2015","journal-title":"Thyroid"},{"key":"2026082106561092400_bib51","doi-asserted-by":"crossref","first-page":"171","DOI":"10.4103\/fjs.fjs_212_20","article-title":"Significance of telomerase reverse-transcriptase promoter mutations in differentiated thyroid cancer","volume":"54","author":"Lai","year":"2021","journal-title":"Formos J Surg"},{"key":"2026082106561092400_bib52","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1186\/s13000-019-0849-6","article-title":"Relevance and clinicopathologic relationship of BRAF V600E, TERT and NRAS mutations for papillary thyroid carcinoma patients in Northwest China","volume":"14","author":"Huang","year":"2019","journal-title":"Diagn Pathol"},{"key":"2026082106561092400_bib53","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1111\/cen.12999","article-title":"TERT promoter mutations are a major indicator of recurrence and death due to papillary thyroid carcinomas","volume":"85","author":"Bullock","year":"2016","journal-title":"Clin Endocrinol"},{"key":"2026082106561092400_bib54","doi-asserted-by":"crossref","first-page":"310","DOI":"10.4132\/jptm.2024.07.29","article-title":"TERT mutations and aggressive histopathologic characteristics of radioiodine-refractory papillary thyroid cancer","volume":"58","author":"Pyo","year":"2024","journal-title":"J Pathol Transl Med"},{"key":"2026082106561092400_bib55","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.ejca.2018.12.003","article-title":"TERT promoter mutations identify a high-risk group in metastasis-free advanced thyroid carcinoma","volume":"108","author":"Bournaud","year":"2019","journal-title":"Eur J Cancer"},{"key":"2026082106561092400_bib56","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1002\/iub.2056","article-title":"TERT promoter mutation in primary papillary thyroid carcinoma lesions predicts absent or lower (131) i uptake in metastases","volume":"71","author":"Meng","year":"2019","journal-title":"IUBMB Life"},{"key":"2026082106561092400_bib57","doi-asserted-by":"crossref","first-page":"258","DOI":"10.2967\/jnumed.116.180240","article-title":"TERT promoter mutation predicts radioiodine-refractory character in distant metastatic differentiated thyroid cancer","volume":"58","author":"Yang","year":"2017","journal-title":"J Nucl Med"},{"key":"2026082106561092400_bib58","doi-asserted-by":"crossref","first-page":"R8","DOI":"10.1530\/EC-17-0010","article-title":"A meta-analysis of prognostic roles of molecular markers in papillary thyroid carcinoma","volume":"6","author":"Vuong","year":"2017","journal-title":"Endocr Connect"},{"key":"2026082106561092400_bib59","article-title":"TERT promoter mutation and its Association with clinicopathological features and prognosis of papillary thyroid cancer: a meta-analysis","volume":"6","author":"Liu","year":"2016","journal-title":"Sci Rep"},{"key":"2026082106561092400_bib60","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1210\/jc.2012-3401","article-title":"Papillary thyroid cancer: time course of recurrences during postsurgery surveillance","volume":"98","author":"Durante","year":"2013","journal-title":"J Clin Endocrinol Metab"}],"container-title":["Endocrine-Related Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/erc.bioscientifica.com\/view\/journals\/erc\/aop\/ERC-25-0424\/ERC-25-0424.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/erc.bioscientifica.com\/downloadpdf\/journals\/erc\/aop\/ERC-25-0424\/ERC-25-0424.xml","content-type":"text\/html","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/journals.bioscientifica.com\/erc\/article-pdf\/doi\/10.1530\/ERC-25-0424\/519690\/erc-25-0424.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/journals.bioscientifica.com\/erc\/article-pdf\/doi\/10.1530\/ERC-25-0424\/519690\/erc-25-0424.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T10:56:24Z","timestamp":1787309784000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.bioscientifica.com\/erc\/article\/33\/8\/e250424\/77516\/Value-of-TERT-promoter-mutations-for-early"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,16]]},"references-count":60,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,8,1]]}},"URL":"https:\/\/doi.org\/10.1530\/erc-25-0424","relation":{},"ISSN":["1351-0088","1479-6821"],"issn-type":[{"value":"1351-0088","type":"print"},{"value":"1479-6821","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,16]]},"article-number":"e250424"}}